RI Research Instruments GmbH, a majority-owned subsidiary of Bruker Energy & Supercon Technologies (BEST), Inc., today announced the award of a $7.7 million contract from the U.S. Department of Energy's Brookhaven National Laboratory (www.bnl.gov).
BERGISCH GLADBACH Germany – April 21, 2010 - RI Research Instruments GmbH, a majority-owned subsidiary of Bruker Energy & Supercon Technologies (BEST), Inc., today announced the award of a $7.7 million contract from the U.S. Department of Energy’s Brookhaven National Laboratory (www.bnl.gov). The contract is for the turn-key supply of a 200 MeV electron injection linear accelerator for BNL’s next-generation National Synchrotron Light Source (NSLS-II).
This new contract covers the engineering, manufacturing, integration, delivery, installation and commissioning of the linear accelerator (linac). Delivery is expected in January 2012. A linac represents the first key element of third generation synchrotron light sources. It generates, accelerates and delivers an electron beam of superior quality to be used in a storage ring for generating x-rays, ultraviolet light and infrared light for research in such diverse fields as biology and medicine, chemistry and environmental sciences, physics, and materials science.
According to a BNL publication, their current light source — the National Synchrotron Light Source (NSLS) — is one of the world’s most widely used scientific facilities. Meeting the critical scientific challenges of the United States energy future will require advanced new capabilities that a new facility called NSLS-II is expected to provide. Construction of the NSLS-II began in 2009 and initial operation is expected in 2015. NSLS-II will be a new state-of-the-art, medium-energy electron storage ring (3 billion electron-volts) designed to deliver world-leading intensity and brightness, and produce x-rays more than 10,000 times brighter than the current NSLS.
Dr. Michael Peiniger, Managing Director of RI Research Instruments, explained: “This award represents the continuation of our business in linear electron accelerator systems and particle accelerating products worldwide. Similar electron linear accelerators have been supplied to major research laboratories in Switzerland, Great Britain, Australia, Germany and are under production for Taiwan and The Netherlands. We are very pleased to have been selected by BNL for the NSLS-II Project, which is expected to have world-leading performance.”
About RI Research Instruments and Bruker Energy & Supercon Technologies, Inc.:
RI Research Instruments GmbH is a world leader in the development and manufacturing of normal and superconducting rf cavities and systems, linear accelerators, as well as special products for physics and energy research, scientific, medical and industrial applications. RI products also include high-performance electron and ion sources, particle beamlines and diagnostics, research reactor subunits as well as vacuum and cryogenic systems. RI Research Instruments was formed as a result of BEST’s April 1, 2009 acquisition of the research instruments business of ACCEL Instruments GmbH from Varian Medical Systems. Bruker acquired a majority stake in RI Research Instruments and retained Dr. Michael Peiniger as Managing Director. BEST has operations in the US, the UK and Germany, and is a wholly-owned subsidiary of Bruker Corporation (NASDAQ: BRKR).
For more information, please visit: www.research-instruments.de or www.bruker-est.com
Cautionary Statement of Bruker Corporation
Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the integration of businesses we have acquired or may acquire in the future, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and government funding policies, changes in governmental regulations, realization of anticipated benefits from economic stimulus programs, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our recent Proxy Statements on Schedule 14A, our annual report on Form 10-K for the year ended December 31, 2009, our most recent quarterly reports on Form 10-Q and our current reports on Form 8-K. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.
RI Research Instruments Contact:
Dr. Michael Peiniger
Managing Director, RI Research Instruments
Tel: +49 2204 843676
Director, RI Research Instruments
Tel: +49 2204 843513